Eli Lilly and Company (India) acknowledged the Haryana drug control authority’s action against counterfeit products falsely labelled as Mounjaro (tirzepatide) seized in Gurugram.

The company clarified that the seized counterfeit products were not manufactured by Lilly and did not originate from its authorised supply chain. It added that, following the authorities’ investigation, most of the fake products have been recovered, and the supply of genuine Lilly medicines through authorised distributors and licensed pharmacies remains uninterrupted.

Winselow Tucker, President and General Manager, Eli Lilly and Company (India), said, “We recognise the efforts of the Haryana regulatory authority in addressing counterfeit medicines and supporting measures aimed at protecting patient safety.”

The company stated that counterfeit products can closely resemble genuine medicines and urged patients, caregivers, and healthcare professionals to stay vigilant. Warning signs include products sourced from unauthorised or unlicensed channels, tampered or damaged packaging, missing batch numbers, expiry dates or manufacturer details, and packaging inconsistencies such as misspellings, unfamiliar logos, or altered labels.

Counterfeit products are not manufactured under approved quality controls and may pose significant risks to patient safety and public health. We will continue to take steps to protect patients from the risks of counterfeit and other unsafe products worldwide, including working with regulators and law enforcement.

“We urge patients to procure Lilly products only through authorised distributors or licensed pharmacies, and on a valid prescription. Further, we want to clarify that Lilly’s patented tirzepatide molecule is marketed in India under two brand names—Mounjaro and Yurpeak,” the company added.